Late chronic catechin antioxidant treatment is deleterious to the endothelial function in aging mice with established atherosclerosis.
Various antioxidants, including polyphenols, prevent the development of atherosclerosis in animal models, contrasting with the failure of antioxidants to provide benefits in patients with established atherosclerosis. We therefore tested in a mouse model the hypothesis that although catechin is atheroprotective in prevention, catechin brings no global vascular protection when initiated after established atherosclerosis, because aging associated with dyslipidemia has induced irreversible dysfunctions. To this end, LDLr(-/-); hApoB(+/+) atherosclerotic (ATX, 9 mo old) and pre-ATX (3 mo old) male mice were treated with catechin (30 mg x kg(-1) x day(-1)) up to 12 mo of age. Vascular function and endothelium/leukocyte interactions were studied at 12 mo old. The renal artery endothelium-dependent dilations were impaired with age whereas adhesion of leukocytes onto the native aortic endothelium was increased (P < 0.05). Aortic oxidative stress [reactive oxygen species (ROS)] increased (P < 0.05) at 3 mo in ATX and at 12 mo in wild-type mice. Aorta mRNA expression of NADPH oxidase increased, whereas that of manganese superoxide dismutase decreased in 12-mo-old ATX mice only. In mice with established ATX, catechin (from 9 to 12 mo) reduced (P < 0.05) by approximately 60% ROS without affecting plaque burden. Notably, catechin worsened endothelial dysfunction and further increased leukocyte adhesion (P < 0.05) in ATX mice. In contrast, the same catechin treatment reversed all age-related dysfunctions in wild-type mice. On the other hand, in pre-ATX mice treated for 9 mo with catechin, plaque burden was reduced by 64% (P < 0.05) and all vascular markers were normalized to the 3-mo-old values. These results demonstrate that an antioxidant treatment is deleterious in mice with established atherosclerosis.
Gendron
Marie-Eve
ME
Department of Physiology, Faculty of Medicine, Université de Montréal, Canada.
Théorêt
Jean-François
JF
Mamarbachi
Aida M
AM
Drouin
Annick
A
Nguyen
Albert
A
Bolduc
Virginie
V
Thorin-Trescases
Nathalie
N
Merhi
Yahye
Y
Thorin
Eric
E
D000375:Aging / Q000502:physiology*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001055:Apolipoproteins B / Q000235:genetics / Q000502:physiology; D050197:Atherosclerosis / Q000378:metabolism / Q000503:physiopathology*; D002392:Catechin / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology*; D008055:Lipids / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018384:Oxidative Stress / Q000502:physiology; D017382:Reactive Oxygen Species / Q000378:metabolism; D011973:Receptors, LDL / Q000235:genetics / Q000502:physiology; D013481:Superoxides / Q000378:metabolism
D000975:Antioxidants; D001055:Apolipoproteins B; D008055:Lipids; D017382:Reactive Oxygen Species; D011973:Receptors, LDL; D013481:Superoxides; D002392:Catechin
Int J Mol Med. 2005 Oct;16(4):533-40
16142383
Biochem Pharmacol. 1988 Mar 1;37(5):837-41
2830882
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4544-9
9539774
Atherosclerosis. 1997 Nov;135(1):37-47
9395271
Pflugers Arch. 2010 May;459(6):1015-23
20107832
Drugs Exp Clin Res. 2002;28(2-3):49-62
12224378
Cardiovasc Res. 2005 Oct 1;68(1):26-36
16009356
Biochem J. 2007 May 15;404(1):1-13
17447894
FEBS Lett. 1998 Aug 14;433(1-2):44-6
9738930
Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2508-15
17644574
Nature. 2003 Sep 11;425(6954):191-6
12939617
Circulation. 2010 Feb 16;121(6):750-8
20124123
Science. 2004 Mar 26;303(5666):2011-5
14976264
Circulation. 2002 Apr 30;105(17):2107-11
11980692
Int J Biochem Cell Biol. 2007;39(1):44-84
16978905
Nat Rev Drug Discov. 2006 Jun;5(6):493-506
16732220
N Engl J Med. 2000 Jul 6;343(1):16-22
10882764
Am J Clin Nutr. 2005 Jan;81(1 Suppl):317S-325S
15640497
Eur J Pharmacol. 2004 Oct 1;500(1-3):299-313
15464042
Circulation. 2008 Jan 22;117(3):421-8
18158360
Pharmacol Ther. 2009 May;122(2):140-9
19285526
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2744-52
9409251
Am J Cardiol. 2008 May 22;101(10A):75D-86D
18474278
Mech Ageing Dev. 2008 May;129(5):261-70
18302967
Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1506-13
9743241
Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H451-8
16980343
Circ Res. 2009 Mar 27;104(6):e42-54
19265038
Am J Clin Nutr. 2001 Oct;74(4):418-25
11566638
Proc Soc Exp Biol Med. 1998 Sep;218(4):376-81
9714083
J Biol Chem. 2005 Apr 29;280(17):17038-45
15684413
Nature. 2006 Nov 16;444(7117):337-42
17086191
Trends Biochem Sci. 2007 Dec;32(12):555-60
17980602
Physiol Res. 2000;49(1):11-8
10805400
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1367-73
15166009
Mech Ageing Dev. 2007 Nov-Dec;128(11-12):662-71
18022214
Am J Cardiol. 2008 May 22;101(10A):14D-19D
18474268
Nature. 2004 Aug 5;430(7000):686-9
15254550
Transplantation. 2007 Dec 15;84(11):1474-82
18091524
Diabetes. 2006 Aug;55(8):2180-91
16873680
Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H689-97
19112095
Can J Physiol Pharmacol. 2008 Nov;86(11):761-9
19011671
Br J Pharmacol. 2009 Jun;157(4):527-36
19630832
Circulation. 2009 Mar 17;119(10):1433-41
19289648
J Nutr. 2001 Jan;131(1):27-32
11208934
Hypertension. 1992 Feb;19(2):117-30
1737645